PMID- 21176158
OWN - NLM
STAT- MEDLINE
DCOM- 20120113
LR  - 20211020
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 10
DP  - 2010 Dec 21
TI  - Cost-effectiveness of six strategies for Helicobacter pylori diagnosis and 
      management in uninvestigated dyspepsia assuming a high resource intensity 
      practice pattern.
PG  - 344
LID - 10.1186/1472-6963-10-344 [doi]
AB  - BACKGROUND: Initial assessment of dyspepsia often includes noninvasive testing 
      for Helicobacter pylori infection. Commercially available tests vary widely in 
      cost and accuracy. Although there is extensive literature on the 
      cost-effectiveness of H. pylori treatment, there is little information comparing 
      the cost-effectiveness of various currently used, noninvasive testing strategies. 
      METHODS: A Markov simulation was used to calculate cost per symptom-free year and 
      cost per correct diagnosis. Uncertainty in outcomes was estimated using 
      probabilistic sensitivity analysis. RESULTS: Under the baseline assumptions, cost 
      per symptom-free year was $122 for empiric proton pump inhibitor (PPI) trial, and 
      costs for the noninvasive test strategies ranged from $123 (stool antigen) to 
      $129 (IgG/IgA combined serology). Confidence intervals had significant overlap. 
      CONCLUSIONS: Under our assumptions for how testing for H. pylori infection is 
      employed in United States medical practice, the available noninvasive tests all 
      have similar cost-effectiveness between one another as well as with empiric PPI 
      trial.
FAU - Holmes, Kyland P
AU  - Holmes KP
AD  - ARUP Laboratories, Salt Lake City, Utah, USA.
FAU - Fang, John C
AU  - Fang JC
FAU - Jackson, Brian R
AU  - Jackson BR
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20101221
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/*economics/therapeutic use
MH  - Combined Modality Therapy
MH  - Cost-Benefit Analysis
MH  - Costs and Cost Analysis/methods
MH  - Disease Management
MH  - Dyspepsia/*drug therapy/*economics
MH  - Female
MH  - Health Resources
MH  - Helicobacter Infections/*diagnosis/*drug therapy/economics
MH  - Helicobacter pylori
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care/statistics & numerical data
MH  - Practice Guidelines as Topic
MH  - Primary Health Care/methods/standards
MH  - Proton Pump Inhibitors/*economics/therapeutic use
MH  - Serologic Tests/economics
MH  - United States
PMC - PMC3022876
EDAT- 2010/12/24 06:00
MHDA- 2012/01/14 06:00
PMCR- 2010/12/21
CRDT- 2010/12/24 06:00
PHST- 2010/05/20 00:00 [received]
PHST- 2010/12/21 00:00 [accepted]
PHST- 2010/12/24 06:00 [entrez]
PHST- 2010/12/24 06:00 [pubmed]
PHST- 2012/01/14 06:00 [medline]
PHST- 2010/12/21 00:00 [pmc-release]
AID - 1472-6963-10-344 [pii]
AID - 10.1186/1472-6963-10-344 [doi]
PST - epublish
SO  - BMC Health Serv Res. 2010 Dec 21;10:344. doi: 10.1186/1472-6963-10-344.